Skip to main content
. 2021 Apr 2;28(6):2037–2045. doi: 10.1111/ene.14829

TABLE 1.

Demographic and clinical characteristics of the cohort

Whole cohort, n = 113
Females a 91 (80.5)
Age, b years 34.2 (8.6)
MS disease duration, b years 7.0 (6.4)
OCB positivity a 110 (97.3)
Relapse in year before baseline a 112 (99.1)
No. of relapses in year before baseline c 1 (0–3)
EDSS at baseline c 1.0 (0–6.5)
EDSS progression in year before baseline a 11 (9.7)
SDMT b 55.3 (9.8)
Received DMT before baseline a 81 (71.7)
No. of DMTs received before baseline c 1 (0–4)
Newly initiated DMT
Interferon β a 32 (28.3)
Glatiramer acetate a 32 (28.3)
Fingolimod a 24 (21.2)
Natalizumab a 25 (22.1)
Previous optic neuritis a 22 (19.5)
pRNFL thickness,μm, at baseline b 92.4 (12.2)
GCIPL thickness, μm, at baseline b 81.1 (12.0)

Abbreviations: DMT, disease‐modifying treatment; EDSS, Expanded Disability Status Scale; GCIPL, macular ganglion cell and inner plexiform layer; MS, multiple sclerosis; OCB, oligoclonal bands; pRNFL, peripapillary retinal nerve fiber layer; SDMT, Symbol Digit Modalities Test.

a

Number (percentage).

b

Mean and standard deviation.

c

Median and range.